Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none

Journal of Clinical Virology

Volumn 76, Issue , 2016, Pages S62-S68

  El Zein, Mariam ^a   Richardson, Lyndsay ^a   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer; Cytology; HPV DNA testing; HPV screening; HPV vaccination; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; DECISION MAKING; FALSE POSITIVE RESULT; GENETIC SCREENING; HUMAN; PAPILLOMAVIRUS INFECTION; PRECANCER; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRAL GENETICS; ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; EARLY CANCER DIAGNOSIS; FEMALE; FORECASTING; GENETICS; GENOTYPING TECHNIQUE; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MASS IMMUNIZATION; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; TRENDS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; FORECASTING; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SCREENING; MASS VACCINATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84960355581     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.11.020     Document Type: Review

References (55)

1. Franco E.L., Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008, 26:A16-A23. 10.1016/j.vaccine.2007.11.069.
2. Isidean S.D., Coutlee F., Franco E.L. Cobas 4800HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Rev. Mol. Diagn. 2014, 14:5-16. 10.1586/14737159.2014.865521.
3. Arbyn M., Ronco G., Anttila A., Meijer C.J.L.M., Poljak M., Ogilvie G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl. 5):F88-F99. 10.1016/j.vaccine.2012.06.095.
4. Dillner J., Rebolj M., Birembaut P., Petry K., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754. 10.1136/bmj.a1754.
5. Franco E.L., Mahmud S.M., Tota J., Ferenczy A., Coutlée F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 2009, 40:478-485. 10.1016/j.arcmed.2009.06.003.
6. McKee S.J., Bergot A.-S., Leggatt G.R. Recent progress in vaccination against human papillomavirus-mediated cervical cancer. Rev. Med. Virol. 2015, 25:54-71.
7. Gardasil 9-A broader HPV vaccine. Med. Lett. Drugs Ther. 2015, 57:47-48.
8. Kirby T. FDA approves new upgraded Gardasil 9. Lancet. Oncol. 2014, 2045:426485. 10.1016/S1470-2045(14) 71191-X.
9. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 2009, 5:705-719.
10. Schiller J.T., Müller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015, 16:e217-e225. 10.1016/S1470-2045(14)71179-9.
11. Kash N., Lee M., Kollipara R., Downing C., Guidry J., Tyring S. Safety and efficacy data on vaccines and immunization to human papillomavirus. J. Clin. Med. 2015, 4:614-633. 10.3390/jcm4040614.
12. Stillo M., Santisteve P.C., Lopalco P.L. Safety of human papillomavirus vaccines: a review. Expert Opin. Drug Saf. 2015, 14:697-712.
13. Petrosky E., Bocchini M., Hairi S., Chesson H., Curtis R., Saraiya M., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination reccomendations of the advisory committee on immunization practices. Morb. Mortal. Wkly. Rep. 2015, 64:300-304.
14. Joura E.A., Giuliano A.R., Iversen O.-E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in women. N. Engl. J. Med. 2015, 372:711-723. 10.1056/nejmoa1405044.
15. Jit M., Brisson M., Laprise J.-F., Choi Y.H. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015, 350:g7584. 10.1136/bmj.g7584.
16. Laprise J.F., Drolet M., Boily M.C., Jit M., Sauvageau C., Franco E.L., et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine 2014, 32:5845-5853. 10.1016/j.vaccine.2014.07.099.
17. Isidean S.D., Tota J.E., Gagnon J.A., Franco E.L. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Rev. Vaccines 2015, 14:119-133. 10.1586/14760584.2015.964213.
18. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30(Suppl. 5):F139-F148. 10.1016/j.vaccine.2012.05.039.
19. Herrero R., González P., Markowitz L.E. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015, 16:e206-e216. 10.1016/S1470-2045(14)70481-4.
20. Drolet M., Bénard E., Boily M., Brisson DSc J., Lemieux-Mellouki P., Mboup A., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2015, 15:565-580. 10.1016/S1473-3099(14)71073-4.
21. Brotherton J.M.L., Fridman M., May C.L., Chappell G., Saville M.A., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092. 10.1016/S0140-6736(11)60551-5.
22. Mariani L., Vici P., Suligoi B., Checcucci-Lisi G., Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv. Ther. 2015, 32:10-30.
23. Malagón T., Drolet M., Boily M.-C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12:781-789. 10.1016/S1473-3099(12)70187-1.
24. Baldur-Felskov B., Dehlendorff C., Munk C., Kjaer S.K. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young danish women. J. Natl. Cancer Inst. 2014, 106. 10.1093/jnci/djt460.
25. Blomberg M., Dehlendorff C., Munk C., Kjaer S.K. Strongly decreased risk of genital warts after vaccination against human papillomavirus: Nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin. Infect. Dis. 2013, 57:929-934. 10.1093/cid/cit436.
26. Leval A., Herweijer E., Ploner A., Eloranta S., Fridman Simard J., Dillner J., et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl. Cancer Inst. 2013, 105:469-474. 10.1093/jnci/djt032.
27. Tabrizi S.N., Brotherton J.M.L., Kaldor J.M., Skinner S.R., Cummins E., Liu B., et al. Fall in human papillomavirus prevalence following a national vaccination program. J. Infect. Dis. 2012, 206:1645-1651. 10.1093/infdis/jis590.
28. Powell S.E., Hariri S., Steinau M., Bauer H.M., Bennett N.M., Bloch K.C., et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012, 31:109-113. 10.1016/j.vaccine.2012.10.092.
29. Mahmud S.M., Kliewer E.V., Lambert P., Bozat-Emre S., Demers A.A. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J. Clin. Oncol. 2014, 32:438-443. 10.1200/JCO.2013.52.4645.
30. FDA approves Gardasil 9 for more types of HPV. Cancer 2015, 1156-1157.
31. Franco E.L., Cuzick J., Hildesheim A., de Sanjosé S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006, 24(Suppl. 3):171-177. 10.1016/j.vaccine.2006.05.061.
32. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J.M., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J. Low. Genit. Tract Dis. 2012, 16:175-204. 10.1097/lgt.0b013e31824ca9d5.
33. Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015, 136:189-197. 10.1016/j.ygyno.2014.11.076.
34. Huh W.K., Ault K., Chelmow D., Davey D., Goulart R., Garcia F., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol. Oncol. 2015, 136:178-182.
35. a Katki H., Kinney W.K., Fetterman B., Lorey T., Poitras N.E., Cheung L., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet. Oncol. 2011, 12:663-672. 10.1016/S1470-2045(11)70145-0.
36. Cuzick J., Szarewski A., Mesher D., Cadman L., Austin J., Perryman K., et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int. J. Cancer 2008, 122:2294-2300. 10.1002/ijc.23339.
37. Louvanto K., Chevarie-Davis M., Ramanakumar A.V., Franco E.L., Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. Am. J. Obstet. Gynecol. 2014, 210. 10.1016/j.ajog.2013.12.033.
38. Blatt A.J., Kennedy R., Luff R.D., Austin R.M., Rabin D.S. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015, 282-288. 10.1002/cncy.21544.
39. Petry K.U., Schmidt D., Scherbring S., Luyten A., Reinecke-Lüthge A., Bergeron C., et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol. Oncol. 2011, 121:505-509. 10.1016/j.ygyno.2011.02.033.
40. Uijterwaal M.H., Polman N.J., Witte B.I., van Kemenade F.J., Rijkaart D., Berkhof J., et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: Baseline and longitudinal data. Int. J. Cancer 2015, 136:2361-2368. 10.1002/ijc.29290.
41. Schiffman M., Vaughan L.M., Raine-Bennett T.R., Castle P.E., Katki H., Gage J.C., et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol. Oncol. 2015, 138:573-578.
42. Verhoef V.M.J., Bosgraaf R.P., van Kemenade F.J., Rozendaal L., Heideman D.a.M., Hesselink A.T., et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014, 15:315-322. 10.1016/S1470-2045(14)70019-1.
43. Louvanto K., Franco E.L., Ramanakumar A.V., Vasiljević N., Scibior-Bentkowska D., Koushik A., et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int. J. Cancer 2015, 136:E638-45. 10.1002/ijc.29196.
44. Depuydt C.E., Jonckheere J., Berth M., Salembier G.M., Vereecken A.J., Bogers J.J. Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. Cancer Med. 2015, 4:1294-1302. 10.1002/cam4.473.
45. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 2005, 97:1072-1079. 10.1093/jnci/dji187.
46. Beer H., Hibbitts S., Brophy S., Rahman M., Waller J., Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK?. Vaccine 2014, 32:1828-1833.
47. Herweijer E., Feldman A.L., Ploner A., Arnheim-Dahlström L., Uhnoo I., Netterlid E., et al. The participation of HPV-vaccinated women in a National cervical screening program: population-based cohort study. PLoS One 2015, 10:e0134185. 10.1371/journal.pone.0134185.
48. Franco E.L., Shinder G.a., Tota J.E., Isidean S.D. Sobering realizations in cancer prevention and screening and their lessons. Prev Med. (Baltim) 2015, 76:129-131. 10.1016/j.ypmed.2015.04.014.
49. Saquib N., Saquib J., Ioannidis J.P. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. Int. J. Epidemiol. 2015, 44:264-277. 10.1093/ije/dyu140.
50. Moyer V. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012, 157:120-134. 10.7326/0003-4819-157-2-201207170-00459.
51. Biller-Andorno N., Jüni P. Abolishing mammography screening programs? A view from the Swiss medical board. N. Engl. J. Med. 2014, 370:1965-1967. 10.1056/nejmp1401875.
52. Franco E.L., Duarte-Franco E., Rohan T.E. Evidence-based policy recommendations on cancer screening and prevention. Cancer Detect. Prev. 2002, 26:350-361.
53. Whitham H.K., Kulasingam S.L. The significantly lower risk of cervical cancer at and after the recommended age to begin and end screening compared to breast and colorectal cancer. Prev. Med. (Baltim) 2015, 76:135-140. 10.1016/j.ypmed.2015.01.035.
54. Castle P.E., Sideri M., Jeronimo J., Solomon D., Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 2007, 197:e1-e6. 10.1016/j.ajog.2007.07.049.
55. Gøtzsche P.C. Commentary: screening: a seductive paradigm that has generally failed us. Int. J. Epidemiol. 2015, 44:278-280. 10.1093/ije/dyu267.